City Therapeutics
Series B
City Therapeutics develops next-generation RNA interference therapies engineered to reach tissues beyond the liver.
Founded
2024City Therapeutics develops next-generation RNA interference therapies engineered to reach tissues beyond the liver.
City Therapeutics is a Cambridge biotechnology company founded in 2024 by RNAi pioneers to engineer next-generation RNA interference therapies. The company has raised roughly $234.5 million across Series A and Series B financings within twenty months and signed a strategic research deal with Biogen valued at up to approximately $1 billion.
The pipeline remains preclinical, anchored by CITY-FXI for thromboembolic disease and CITY-RBP4 for Stargardt disease, with additional discovery programs in ocular and central nervous system indications. Investors include ARCH Venture Partners, Invus, Fidelity, Regeneron, Viking Global, Sofinnova Investments, RTW, Rock Springs Capital, and SlatePath.
City Therapeutics builds an RNA interference platform combining engineered siRNA trigger molecules with targeting ligands designed to deliver gene-silencing therapies to tissues beyond the liver. Its proprietary cleavage-inducing tiny (city) RNAs aim to improve potency and durability over earlier-generation siRNA chemistries.
The current pipeline comprises CITY-FXI, an RNAi candidate against hepatic Factor XI for thromboembolic disease that has reached IND/CTA-enabling stage, and CITY-RBP4, a preclinical program for Stargardt disease delivered to the eye. Additional discovery-stage programs target central nervous system and geographic atrophy indications.
City Therapeutics is led by RNAi field founders and operators, including Alnylam co-founder John Maraganore as executive chair and chief executive Andy Orth, giving the company deep institutional expertise in siRNA chemistry, GalNAc-style targeting, and clinical translation of RNA interference therapeutics.
Its proprietary cleavage-inducing tiny RNA triggers and tissue-targeting ligands aim to extend RNAi reach beyond hepatic indications to ocular and central nervous system tissues, supported by capital from ARCH Venture Partners, Fidelity, Invus, Regeneron, Viking Global, and Sofinnova Investments and validated by a strategic collaboration with Biogen worth up to approximately $1 billion.